Vanda Pharmaceuticals (VNDA) Phase III EPIONE study of tradipitant did not meet its primary endpoint

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. HOOD
7. DFTX
8. GOOGL
9. MU
10. IBM

Go back to Vanda Pharmaceuticals (VNDA) Phase III EPIONE study of tradipitant did not meet its primary endpoint

Vanda Pharmaceuticals (VNDA) Misses Q4 EPS by 3c

February 25, 2020 4:03 PM EST

Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q4 EPS of $0.08, $0.03 worse than the analyst estimate of $0.11. Revenue for the quarter came in at $60.9 million versus the consensus estimate of $59.57 million.

"We had another year of outstanding commercial growth," said Mihael H. Polymeropoulos,... More

Vanda Pharmaceuticals (VNDA) Halted, News Pending

February 25, 2020 4:03 PM EST

Vanda Pharmaceuticals (NASDAQ: VNDA) Halted, News Pending

... More